Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 MillionPRNewsWire • 12/20/23
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE AmericanPRNewsWire • 12/18/23
Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdatePRNewsWire • 11/14/23
Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023PRNewsWire • 11/09/23
Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue ResultsPRNewsWire • 10/19/23
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese PatientsPRNewsWire • 10/18/23
Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis TreatmentPRNewsWire • 10/16/23
Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 09/28/23
Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023PRNewsWire • 09/22/23
Palatin to Present at the H.C. Wainwright 25th Annual Global Investment ConferencePRNewsWire • 09/07/23
Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye DiseasePRNewsWire • 09/07/23
Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i TreatmentPRNewsWire • 08/10/23
Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical StudyPRNewsWire • 08/08/23
Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi®PRNewsWire • 08/07/23
Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi® Product Revenue ResultsPRNewsWire • 07/11/23
Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte ConferencePRNewsWire • 05/30/23